Navigation Links
Valeant Pharmaceuticals Announces Increase to Monetary Limit Under Its Securities Repurchase Program
Date:8/29/2011

MISSISSAUGA, Ontario, Aug. 29, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (the "Company" or "Valeant") announced today that its Board of Directors has approved an increase of $300 million under its previously announced securities repurchase program (the "Securities Repurchase Program").  Under the Securities Repurchase Program, Valeant may now repurchase up to $1.8 billion of its convertible notes, senior notes, common shares and/or other notes or shares that may be issued prior to the completion of the program. As part of this Securities Repurchase Program, Valeant also recently announced that it had filed a Notice of Intention to make a normal course issuer bid to repurchase up to 1,000,000 of its common shares through the facilities of the Toronto Stock Exchange ("TSX").

The Securities Repurchase Program will terminate on November 7, 2011 or at such time as Valeant completes its purchases.  To date, the Company has purchased 14,969,599 of its common shares for aggregate consideration of $590.6 million and a total of $302.5 million principal amount of its 5.375% Convertible Notes for aggregate consideration of $806.3 million. The amount of securities to be purchased and the timing of purchases under the Securities Repurchase Program may be subject to various factors, which may include the price of the securities, general market conditions, corporate and regulatory requirements, alternate investment opportunities and restrictions under the Company's financing agreements. The securities to be repurchased will be funded using Valeant's cash resources.

Valeant believes that the proposed purchases are in the best interests of the Company and are a desirable use of corporate funds. The Securities Repurchase Program may be modified, suspended or terminated at any time without prior notice.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Caution Regarding Forward-Looking Information

To the extent any statements made in this document contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information as defined under applicable Canadian securities legislation (collectively, "forward-looking statements").

This press release may contain forward-looking statements. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements, which include statements regarding future repurchases under the securities repurchase program, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report filed with the SEC and risks and uncertainties as detailed from time to time in Valeant's filings with the SEC and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant to Acquire Polish Products
2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
6. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
7. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
8. Valeant Announces Pricing of Senior Notes
9. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
10. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
11. Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... -- Trifecta Clinical , a leading global provider ... Ward to Vice President of Commercial Operations.  Rick ... the promotion of Ericka Atkinson to Vice ... joins Trifecta from Greenphire where he was Vice President ... positions within the healthcare industry throughout his career.  "Rick ...
(Date:1/24/2017)... Results show Gamma Knife spares normal brain tissue ... Elekta (EKTA-B.ST) today announced new data demonstrating ... a higher radiation dose compared to linear accelerator (linac)-based delivery ... complex brain tumors, were published in the Journal ... ...
(Date:1/24/2017)... , January 24, 2017 www.Financialbuzz.com ... growing industries in the United States ... in 2016. In addition, Proposition 64, the California Cannabis Legalization ... 42.87% against on November 8, 2016. This outcome means that ... use and to grow a certain amount of cannabis for ...
Breaking Medicine Technology:
(Date:1/24/2017)... Santa Rosa, California (PRWEB) , ... January 24, 2017 , ... ... named Cary McNamara as chief financial officer. , “Cary’s broad financial ... individual who possesses both the strategic planning and day-to-day financial operations skills we need ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... advance to the semi-final round of the 2017 Cupid's Cup Entrepreneurship Competition. Chaired ... its 12th year in 2017. The entrepreneurs will showcase their businesses on February ...
(Date:1/24/2017)... ... January 24, 2017 , ... His message has been heard by ... organization End Distracted Driving , Joel Feldman, has reached his biggest national audience ... in one of the top newspapers in circulation in the country, and he hopes ...
(Date:1/24/2017)... Hill, N.C. (PRWEB) , ... January 24, 2017 ... ... Trump Administration is the focus of a new report from the Frank ... Kenan-Flagler Business School. , Influential business leaders, academics and policy makers identified concrete ...
(Date:1/24/2017)... ... , ... The NewKILO JRP, a three-year project of the European Metrology Research ... (EU), was completed in May 2015. The future definition will require the unit of ... which presents some challenges to establishing traceability to the mass scale. , This ...
Breaking Medicine News(10 mins):